Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis

Arthritis and Rheumatism

Volumn 63, Issue 3, 2011, Pages 775-782

  Herrick, Ariane L ^a   Van Den Hoogen, Frank ^b   Gabrielli, Armando ^c   Tamimi, Nihad ^d   Reid, Carol ^d   O'Connell, Damian ^d   Vázquez Abad, Maria Dolores ^e   Denton, Christopher P ^f  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b SINT MAARTENSKLINIEK   (Netherlands)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^e PFIZER INC   (United States)

^f ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CELL ADHESION MOLECULE; INTERCELLULAR ADHESION MOLECULE PROTEIN; N TERMINAL TYPE I PROCOLLAGEN PROPEPTIDE; PLACEBO; PROCOLLAGEN; SILDENAFIL; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE PROTEIN;

ADULT; AGED; ARTHRALGIA; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ENDOTHELIAL DYSFUNCTION; FACE EDEMA; FEMALE; FLATULENCE; GASTROENTERITIS; HEART PALPITATION; HEART RATE; HUMAN; LIMITED CUTANEOUS SYSTEMIC SCLEROSIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MUSCLE HYPERTONIA; MYALGIA; PAIN ASSESSMENT; PERIPHERAL ARTERIAL TONOMETRY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAYNAUD CONDITION SCORE; RAYNAUD PHENOMENON; RESPIRATORY TRACT INFECTION; RISK REDUCTION; RP PAIN SCORE; SCLERODERMA; SCORING SYSTEM; SIDE EFFECT; SYSTEMIC SCLEROSIS; THORAX PAIN; TONOMETRY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; BIOLOGICAL MARKERS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PURINES; RAYNAUD DISEASE; RECURRENCE; SCLERODERMA, LIMITED; SULFONES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 79953696248     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30195     Document Type: Article

References (39)

1. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988;15:202-5. (Pubitemid 18073738)
2. Generini S, Matucci Cerinic M. Raynaud's phenomenon and vascular disease in systemic sclerosis. Adv Exp Med Biol 1999;455: 93-100. (Pubitemid 32187446)
3. Varga J. Systemic sclerosis: an update. Bull NYU Hosp Jt Dis 2008;66:198-202.
4. Abraham D, Distler O. How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther 2007;9 Suppl 2:S2.
5. Bonetti PO, Barsness GW, Keelan PC, Schnell TI, Pumper GM, Kuvin JT, et al. Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol 2003;41:1761-8. (Pubitemid 36584250)
6. Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Kuvin JT, Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol 2004;44:2137-41. (Pubitemid 39576032)
7. Rubinshtein R, Kuvin JT, Soffler M, Lennon RJ, Lavi S, Nelson RE, et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J 2010;31:1142-8.
8. Denton CP, Bickerstaff MC, Shiwen X, Carulli MT, Haskard DO, Dubois RM, et al. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol 1995;34:1048-54. (Pubitemid 26013507)
9. Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, et al, on behalf of the CAT-192 Study Group and the Scleroderma Clinical Trials Consortium. Recombinant human antitransforming growth factor β1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007;56:323-33. (Pubitemid 46106206)
10. Kikuchi K, Ihn H, Sato S, Igarashi A, Soma Y, Ishibashi Y, et al. Serum concentration of procollagen type I carboxyterminal propeptide in systemic sclerosis. Arch Dermatol Res 1994;286:77-80. (Pubitemid 24025572)
11. Gruschwitz MS, Hornstein OP, von den Driesch P. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum 1995;38:184-9.
12. Iannone F, Riccardi MT, Guiducci S, Bizzoca R, Cinelli M, Matucci-Cerinic M, et al. Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. Ann Rheum Dis 2008;67:1121-6.
13. Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999; 42:2646-55. (Pubitemid 30327186)
14. De LaVega AJ, Derk CT. Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication. Expert Opin Investig Drugs 2009;18:23-9.
15. Torley HI, Madhok R, Capell HA, Brouwer RM, Maddison PJ, Black CM, et al. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Ann Rheum Dis 1991;50:800-4.
16. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994;120:199-206.
17. Wigley FM. Clinical practice: Raynaud's phenomenon. N Engl J Med 2002;347:1001-8.
18. Levien TL. Phosphodiesterase inhibitors in Raynaud's phenomenon. Ann Pharmacother 2006;40:1388-93. (Pubitemid 44204971)
19. Data on file. New York (NY): Pfizer Inc; 2002.
20. Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, et al, for the Scleroderma Clinical Trials Consortium. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002;46: 2410-20.
21. Fries R, Shariat K, von Wilmowsky H, Bohm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005;112:2980-5. (Pubitemid 41612301)
22. Zamiri B, Koman AL, Smith BP, Smith TL, Holden M, Rushing J, et al. Double-blind, placebo-controlled trial of sildenafil for the management of primary Raynaud's phenomenon. Ann Rheum Dis 2004;63 Suppl 1:484-5.
23. Colglazier CL, SutejPG, O'Rourke KS. Severe refractory fingertip ulcerations in a patient with scleroderma: successful treatment with sildenafil. J Rheumatol 2005;32:2440-2. (Pubitemid 41780663)
24. Pakozdi A, Howell K, Black CM, Denton CP. Addition of the short term phosphodiesterase-5 inhibitor sildenafil to iloprost therapy for scleroderma digital vasculopathy [abstract]. Arthritis Rheum 2007;56 Suppl:S825-6.
25. Carlino G. Treatment of Raynaud's phenomenon with tadalafil, a phosphodiesterase-5 inhibitor [abstract]. Ann Rheum Dis 2005;64 Suppl III:iii258.
26. Brueckner CS, Becker MO, Kroencke T, Huscher D, Scherer HU, Worm M, et al. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis 2010;69:1475-8.
27. Schiopu E, Hsu VM, Impens AJ, Rothman JA, McCloskey DA, Wilson JE, et al. Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. J Rheumatol 2009;36:2264-8.
28. Caglayan E, Huntgeburth M, Karasch T, Weihrauch J, Hunzelmann N, Krieg T, et al. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med 2006;166:231-3. (Pubitemid 43144949)
29. Harrison BJ, Silman AJ, Hider SL, Herrick AL. Cigarette smoking as a significant risk factor for digital vascular disease in patients with systemic sclerosis. Arthritis Rheum 2002;46:3312-6. (Pubitemid 35453542)
30. Kumar N, Griffiths B, Allen J. Thermographic and symptomatic effect of a single dose of sildenafil citrate on Raynaud's phenomenon in patients with systemic sclerosis: a potential treatment. J Rheumatol 2006;33:1918-9. (Pubitemid 44373247)
31. Kamata Y, Kamimura T, Iwamoto M, Minota S. Comparable effects of sildenafil citrate and alprostadil on severe Raynaud's phenomenon in a patient with systemic sclerosis. Clin Exp Dermatol 2005;30:451. (Pubitemid 40835363)
32. Rosenkranz S, Diet F, Karasch T, Weihrauch J, Wassermann K, Erdmann E. Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the raynaud phenomenon. Ann Intern Med 2003;139:871-3.
33. Ihn H, Sato S, Fujimoto M, Kikuchi K, Kadono T, Tamaki K, et al. Circulating intercellular adhesion molecule-1 in the sera of patients with systemic sclerosis: enhancement by inflammatory cytokines. Br J Rheumatol 1997;36:1270-5.
34. Ihn H, Sato S, Fujimoto M, Takehara K, Tamaki K. Increased serum levels of soluble vascular cell adhesion molecule-1 and E-selectin in patients with systemic sclerosis. Br J Rheumatol 1998;37:1188-92.
35. Scheja A, Wildt M, Wollheim FA, Akesson A, Saxne T. Circulating collagen metabolites in systemic sclerosis: differences between limited and diffuse form and relationship with pulmonary involvement. Rheumatology (Oxford) 2000;39:1110-3.
36. Di Ciaula A, Covelli M, Berardino M, Wang DQ, Lapadula G, Palasciano G, et al. Gastrointestinal symptoms and motility disorders in patients with systemic scleroderma. BMC Gastroenterol 2008;8:7.
37. Padma-Nathan H, Eardley I, Kloner RA, Laties AM, Montorsi F. A 4-year update on the safety of sildenafil citrate (Viagra). Urology 2002;60 Suppl 2B:69-74.
38. Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res 1998;10:69-73.
39. Padma-Nathan H. Sildenafil citrate (Viagra) treatment for erectile dysfunction: an updated profile ofresponse and effectiveness. Int J Impot Res 2006;18:423-31. (Pubitemid 44330291)